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be insufﬁcient to identify Treg in humans. To determine whether
the ICOS T-cell populations which were modulated with ECP
treatment were functionally Treg, we isolated CD4CD25
ICOS and CD4CD25 ICOS- cells from patients with
cGVHD before and after ECP therapy and demonstrated that the
CD4CD25ICOS cells functioned as suppressors in an MLR
reaction, suggesting that these cells represent Treg cells. We
conclude that these ICOSCD25CD4 T-helper cells may rep-
resent, in part, immunoregulatory T-cells implicated in the induc-
tion of tolerance. We propose that the mechanism of action of
ECP in cGVHD involves both modulation of DC to induce mat-
uration markers, including possibly the ligand for ICOS (B7H2), as
well as the induction of ICOS expressing CD25 immunoregula-
tory T-helper cells.
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DEFECTIVE POPULATIONS OF REGULATORY T CELLS CORRELATE
WITH THE OCCURRENCE OF CHRONIC GRAFT VERSUS HOST DISEASE
AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Zorn, E., Floyd, B., Lee, S.J., Soiffer, R.J., Antin, J.H., Ritz, J.
Dana-Farber Cancer Institute, Boston, MA
Chronic-Graft-Versus-Host-Disease (cGVHD) is a major com-
plication of hematopoietic stem cell transplantation (HSCT). Al-
though the precise etiology of cGVHD is still unknown, recent
evidence suggests that defects in regulation of donor immunity
play an important role in this disease. CD4CD25 regulatory T
cells (T-regs) are critical elements of immune regulation in normal
individuals. T-regs develop in the thymus and reach the periphery
where they inhibit autoreactive effector T cells. After HSCT the
number of recipient hematopoietic cells, including T-regs, are
severely reduced. In adults, residual thymic function is also affected
after transplantation, limiting the reconstitution of CD4CD25
T cells in the periphery. We hypothesized that the occurrence of
cGVHD correlates with a quantitative and qualitative defect in
T-regs reﬂecting a global deregulation of the immune system.
PBMC collected from 29 patients with mild, moderate or severe
cGVHD (group-A), 7 patients who had cGVHD but had resolved
their disease (group-B), and 15 healthy controls (group-C) were
analyzed by complementary methods to assess circulating popula-
tions of T-regs. 1) Percentages of circulating CD4CD25 cells
in total PBL were compared for the 3 groups. 2) Expression of the
T-reg speciﬁc transcription factor foxP3 was assessed by quantita-
tive PCR and reported as a function of CD3 cells. 3) Functional
activity of CD25 T-regs was measured using an in vitro assay
based on the modulation of viral antigen reactive CD8 T cells.
Phenotypic and molecular results were consistent and showed a
signiﬁcant decrease in circulating CD4CD25 cells as well as
lower expression of foxP3 in group A compared to control group
C. Patients with resolved cGVHD (group B) were indistinguish-
able from healthy donors either phenotypically or using the mo-
lecular assay, suggesting that they had recovered normal levels of
T-regs. In functional assays, using samples from cGVHD patients
(group A), a correlation was found between the quantitative assess-
ment of T-regs and their capacity to inhibit class-I anti-viral
effector T cells. In conclusion, these experiments strongly support
our hypothesis that a defect in CD4CD25 T cell populations
correlates with cGVHD and establishes a framework for the de-
velopment of new therapeutic interventions for this disease.
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DONOR T CELL-DERIVED TNF ALPHA REGULATES PULMONARY CHE-
MOKINE EXPRESSION AND THE DEVELOPMENT OF IDIOPATHIC PNEU-
MONIA SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTA-
TION
Hildebrandt, G.C.1, Olkiewicz, K.M.1, Corrion, L.1, Chang, Y.2, Liu,
C.3, Ferrara, J.L.M.1, Cooke, K.R.1 1. Dept. of Pediatrics; BMT
Program, University of Michigan, Ann Arbor, MI; 2. Dept. of Pathol-
ogy, University of Michigan, Ann Arbor, MI; 3. Dept. of Pathology,
University of Florida School of Medicine, Gainesville, FL
TNFa is a primary effector molecule in the pathophysiology of
Idiopathic Pneumonia Syndrome (IPS), a frequently fatal compli-
cation after allogeneic (allo) stem cell transplantation (SCT). How-
ever, the contribution of host versus donor derived TNFa to the
development of IPS remains to be determined. Using a lethally
irradiated B6B6D2F1 mouse SCT model, we found that signif-
icant lung injury was present by week 5 after allo SCT compared
to syn controls. Both pulmonary macrophages and T cells were
completely of donor origin at this time. Furthermore, numbers of
TNFa secreting CD4 and CD8 T cells were signiﬁcantly increased
in the BAL ﬂuid (BALF) after allo SCT (CD8: 154 15 vs 2 0.2,
CD4: 76 7 vs 29 2 (x1000)) and pulmonary macrophages from
allo mice secreted signiﬁcantly more TNFa when restimulated
with LPS in vitro (357  127 vs 136  31 pg/ml). We therefore
hypothesized that donor cell-derived TNFa is important to devel-
opment of IPS and tested this by using B6 wild type (wt) or B6
TNFa-/- mice as allo SCT donors: TNFa-/- SCT resulted in
signiﬁcantly reduced lung injury(1.2  0.3 vs 4.1  0.7) and BALF
TNF levels (4.8  3.7 vs 67.4  27.0 pg/ml) compared to wt
controls. These ﬁndings were conﬁrmed in two other allo SCT
systems wherein donor and host differ either at class I or II MHC
only (B6bm1 or B6bm12). In addition, lung injury did not
differ between groups when B6TNFa-/- mice were used as recip-
ients in the bm1B6 system. To determine the contribution of
donor accessory (bone marrow) cell- versus T cell-derived TNFa,
we completed mixing experiments in the B6F1 system wherein
wt or TNFa-/- bone marrow (BM) was supplemented with either
wt or TNFa-/- T cells and found that TNFa from both cellular
sources contributes to IPS. Interestingly, the absence of TNFa
from donor T cells alone was sufﬁcient to signiﬁcantly reduce
levels of the inﬂammatory chemokines MIG, RANTES, MIP-1a,
MCP-1 in the lung by week 2 after SCT. Decreased chemokine
expression directly correlated with the recruitment of inﬂamma-
tory cells to the lung; the severity of IPS was completely abrogated
after allo SCT with wt BM and TNFa-/- T cells (syn: 1.1  0.4;
allo contrl: 4.4  0.6; TNFa-/- T: 2.2  0.9). In conclusion, our
data demonstrate that donor derived TNFa is critical to the de-
velopment of IPS and reveal thus far an unrecognized role for T
cell derived TNFa in the regulation of pulmonary chemokine
expression and the subsequent recruitment of donor effector cells
to the lung after allo SCT.
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SELECTIVE DEPLETION OF T CELL CLONES RESPONSIBLE FOR GVHD
IN A MURINE MODEL
Kappel, B.J., Eng, J.M., Pinilla-Ibarz, J., van den Brink, M.M.R.M.,
Scheinberg, D.A. Memorial Sloan-Kettering Cancer Center, New York,
NY
Graft-versus-host-disease (GVHD), the single most important
complication post allogeneic bone marrow transplantation (BMT),
arises from donor T cell anti-host activity due to mismatches in
major and/or minor histocompatability complexes (MHC and/or
mHAg). Upon encountering a foreign antigen donor T cells un-
dergo antigen speciﬁc clonal expansion, greatly increasing the
number of donor anti-host T cells in circulation. Current therapies
for GVHD include complete non-speciﬁc T cell depletion of bone
marrow (TCD-BM) prior to BMT or immunosuppression post
BMT. However, the use of peptide speciﬁc MHC tetramers allows
for detection of these antigen speciﬁc alloreactive T cell clones.
We hypothesize that speciﬁc targeting and deletion of these T cells
responsible for anti-host activity could prove to be an effective
immunotherapy for the elimination of GVHD.
We have chosen as a murine model of study C57BL/6 (B6) 3
BALB.B, an H2Kb MHC-matched BMT model with one de-
scribed immunodominant mHAg mismatch. This mismatch occurs
at the H60 locus and foreign CD8 T cell receptors recognize a
peptide octamer known as the LYL8 epitope. We propose to show
that the antigen speciﬁc T cells are present, functional, capable of
causing GVHD and removable from the larger population of T
cells. Using phycoerythrin (PE) labeled LYL8 tetramers we iden-
tiﬁed the expanding population of speciﬁc B6 anti-BALB.B T cells
within the spleens of B6 mice immunized with irradiated BALB.B
splenocytes. We then characterized the proliferative and functional
ability of these T cells with mixed lymphocyte reactions and 
-IFN
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ELISPOT assays. In order to remove these speciﬁc T cells from
the entire splenocyte population we took advantage of the PE
labeling on the LYL8 tetramer. Using anti-PE microbeads and
AUTOMACS separation, we have successfully depleted LYL8
tetramer positive T cells from both naı¨ve and immunized B6
spleens. Finally, we have been able to demonstrate that ex vivo
depletion of tetramer positive cells from naı¨ve B6 splenocytes prior
to adoptive transfer along with TCD-BM signiﬁcantly delayed the
onset of lethal GVHD post BMT (see table).
We have shown that speciﬁc depletion of antigen speciﬁc T cells
is a feasible and successful method for the elimination of GVHD in
this model.
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THERAPY FOR REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE
(AGVHD) WITH BASILIXIMAB (BAMAB) - A SELECTIVE INTERLEUKIN-2
RECEPTOR (IL-2R) ANTAGONIST
Moreira, V.A., Bonﬁm, C.M., Bitencourt, M.A., Setubal, D.C., Loren-
zato, C., Ruiz, J., Zanis-Netto, J., de Medeiros, C.R., Pasquini, R. BMT
Center-Federal University of Parana, Curitiba, PR, Brazil
BaMab is a chimeric murin-human monoclonal antibody, which
binds to the alpha chain of IL-2R found predominantly on acti-
vated cytotoxic T-cells. The IL-2 activation of RAS pathway,
which activates lymphocyte proliferation, differentiation and de-
velopment of a-GVHD, is inhibited by this drug through a com-
petitive antagonism. We report our experience with BaMab as
therapy for refractory a-GVHD after BMT. Thirty-four patients
(pts) with severe refractory a-GVHD received BaMab from de-
cember 1998 to october, 2003. The latest 21 pts were treated as
part of a prospective protocol. Because of a 7 days (d) half-life,
BaMab schedule was 40mg weekly for 2-3 doses (adults) and 20
weekly for 2-3 doses (children). Age: 2-38 years (y) (M: 13 y); Sex
M/F: 21/13. Unrelated BMT: 25 pts; related BMT: 9 pts. Cell
source: Bone marrow: 30; Cord blood: 4. Diagnosis: AML(4 pts),
ALL(4 pts), MDS(4 pts), CML(9 pts), Fanconi anemia (9 pts), AAS
(3 pts), other (1pt). All pts had a-GVHD grade III-IV, manifesting
from day 6-248 after transplant (M: 24 d), when in use of cyclo-
sporin, and refractory to association with steroids (2-5mg/kg/d) for
7 to 70 d (M: 17 d). Sites of GVHD involvement: skin: 32 pts; GI:
25 pts; liver: 23pts. The ﬁrst administration day of BaMab occurred
between 21-256 d after BMT (M: 42 d). Median follow-up was
196 d (range: 35-1847 d). Overall response rate was 82% (CR: 11
pts, PR: 17 pts). Two pts (8 %) were not evaluated due to early
death. Skin GVHD CR (complete response): 27/32 pts (84,3 %),
PR (partial response) : 4/32 (12,5 %), NR (no response) :
1/32(3,2%); GI GVHD CR: 12/25 pts (48 %), PR: 8/25 pts(32 %),
NR : 4/25(16%), NA (not available): 1/25 (4%); liver GVHD CR
: 6/23 pt (26%), PR:7/23 (30,5%), NR : 8/23 pts (34,7%), NA:
2/23(8,8). Time to ﬁrst signs of response was 1-30 d (M: 7 d).
Duration of response varied from 5-1103 d (M: 38 d). There were
no infusion-related reactions. Estimated 5 y overall survival: 32%.
Eleven (11) pts are alive, 7 pts with CR, 3 PR and 1 pt SR (with
isolated skin GVHD). Main causes of death included: disseminated
CMV (4 pt), fungal infection (6 pts), sepsis (8 pts), haemorrhage
(2pts), and relapse (2 pts with ALL). GVHD relapses were seen on
14/34 pts (41%), but 7 pts (28%) were rescued with another
therapy (MMF, PUVA, steroids). BaMab administration is safe and
this drug is useful to treat refractory a-GVHD. Prospective studies
are necessary to evaluate its optimal treatment schedule and efﬁ-
cacy.
HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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RESULTS OF THE CORD BLOOD TRANSPLANTATION STUDY (COBLT)
UNRELATED DONOR BANKING PROGRAM
Kurtzberg, J.1, Wagner, E.L.2, Fraser, J.K.3, Cairo, M.S.4, Jensen, L.2,
Cohen, G.5, Carter, S.L.5, Kernan, N.A.6 1. Duke University Medical
Center, Durham, NC; 2. National Heart, Lung, and Blood Institute,
Bethesda, MD; 3. University of California at Los Angeles, Los Angeles,
CA; 4. Georgetown University Medical Center, Washington, DC; 5.
The Emmes Corporation, Rockville, MD; 6. Memorial Sloan Kettering
Cancer Center, New York, NY
The COBLT banking program, initiated in 1996 with support
from the National Heart Lung and Blood Institute aimed to 1)
develop standard operating procedures (SOPs) for donor screen-
ing, recruitment and consenting and for collection, testing, pro-
cessing, cryopreservation, and thawing of unrelated donor umbil-
ical cord blood (UCB) and 2) build an ethnically diverse unrelated
cord blood bank to support a transplantation research protocol.
The program included multiple collection sites, 3 banks, a steering
committee and coordinating center which developed a web based
data collection system. Collections were initiated 12/97 and com-
pleted 7/2001. Screening data for 34,799 potential donors were
collected from 4/98 to 3/2001. Of these 10,599 (30%) were not
approached due to lack of informed consent or a COBLT exclu-
sion criterion. A total 20,710 mothers (60% of screened) were
approached and consented to participate in the program and UCB
was collected from 48 % of those screened and 81% of those
consented. 17,207 cord blood units (CBUs) of diverse ethnicity
were collected (40% Caucasian; 17% African-American; 11%
Asian; 20% Hispanic; 13% Mixed/Other). Of these, 11,096 (64%)
were cryopreserved and placed in quarantine. Of these, 49% passed
all eligibility criteria, were HLA-typed and entered into the
COBLT search registry. The reasons for exclusion after collection
were insufﬁcient volume or cell count (64%), a positive maternal
infectious disease test (8%) or a risk factor in the maternal history
(8%). The mean total viable nucleated, CD34, and CD3 cell
counts for the banked units were 9.2x10e8, 3.4x10e6 and 1.8x10e8,
respectively. The mean total CFU-GM count was 9.3x10e5. Rela-
tionships between ethnicity, route of delivery, birth weight, ma-
ternal age, gestational age, infant gender and UCB yields in banked
CBUs were examined. Higher cord blood volumes and total nu-
cleated cell count (TNC) were obtained from C-section compared
to vaginal deliveries. Units from African American donors con-
tained lower TNC counts per volume compared to other ethnici-
ties. UCB volume, TNC and CD34 cell content correlated with
birth weight. CD34 content decreased with increasing gesta-
tional age. The COBLT Program demonstrates that SOPs for
donor recruitment and consenting, collection, processing, cryo-
preservation, quality assurance, and data collection can be success-
fully developed and implemented in multiple banks coordinated by
a single coordinating center.
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EMBRYONIC STEM CELLS AS AN ALTERNATIVE DONOR MARROW
SOURCE: ENGRAFTMENT WITHOUT GVHD
Burt, R.K., Oyama, Y., Verda, L. Northwestern University, Chicago, IL
Hematopoietic stem cells (HSCs) have been considered unique
in their ability to reconstitute hematopoiesis following transplan-
tation into an immune compromised host. HSCs cannot be re-
newed ex vivo and must be individually collected from each donor
or patient resulting in inter-patient as well as intra-patient lot
Table. Clonal Deletion of LYL8-speciﬁc T Cells Prior to Adoptive
Transfer Signiﬁcantly Delays the Onset of GVHD
B6 Bone Marrow  N
Median
Survival
(Days)
P
Value
B6 T Cells 9 14 0.0055
LYL8- B6 T Cells 9 31
HSV8-B6 T Cells
(non-specific
control) 4 8 0.0003
*P values compare indicated group to LYL8- B6 T cells group.
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